COSCIENS Biopharma Inc
TSX:CSCI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
COSCIENS Biopharma Inc
Total Liabilities & Equity
COSCIENS Biopharma Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
COSCIENS Biopharma Inc
TSX:CSCI
|
Total Liabilities & Equity
$21.4m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Liabilities & Equity
CA$84.4m
|
CAGR 3-Years
62%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Liabilities & Equity
$751.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
36%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Liabilities & Equity
$633.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
27%
|
CAGR 10-Years
26%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Liabilities & Equity
CA$86.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Liabilities & Equity
$221.5m
|
CAGR 3-Years
110%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
COSCIENS Biopharma Inc
Glance View
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
See Also
What is COSCIENS Biopharma Inc's Total Liabilities & Equity?
Total Liabilities & Equity
21.4m
USD
Based on the financial report for Dec 31, 2025, COSCIENS Biopharma Inc's Total Liabilities & Equity amounts to 21.4m USD.
What is COSCIENS Biopharma Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-8%
Over the last year, the Total Liabilities & Equity growth was -39%. The average annual Total Liabilities & Equity growth rates for COSCIENS Biopharma Inc have been -27% over the past three years , -10% over the past five years , and -8% over the past ten years .
